openPR Logo
Press release

HIV Drug Market Growth by Top Manufacturers – Boehringer Ingelheim International GmbH, Merck & Co., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd. & Cipla Limited & Others

11-29-2018 07:44 PM CET | Health & Medicine

Press release from: Allied Market Research

HIV Drug Market Growth by Top Manufacturers – Boehringer

Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to garner $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016-2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS).

The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, stringent government regulations for the approval and commercialization of HIV drugs is expected to restrain the industry growth.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/1867?utm_source=OPR

Multi-class combination drugs segment had accounted for more than one-third revenue of the overall HIV drug market in 2015, owing to increase in adoption of combination drugs from this medication class due to their better results in the control of HIV & related coinfections and their ease in consumption & adherence. Increase in the number of HIV infected patients across the globe increases the need for effective treatment for HIV related diseases. Use of Multi-class combination products is an efficient way of treating HIV. Atripla and Prezista are among the blockbuster combination drugs used in the HIV treatment.

North America was the highest revenue contributor in 2015; this is attributed to the awareness about healthcare in the region, higher HIV diagnosis & treatment rate, ample healthcare expenditure, well-established healthcare system, and proactive government initiatives to control the spread of HIV in the North American countries. Gilead, GlaxoSmithKline, Novartis, and Merck & Co. are some of the key players in the North American HIV drugs market. However, Asia-Pacific region is projected to grow with the highest CAGR of 6.3% during the analysis period, due to the presence large HIV patient pool and ample growth opportunities in terms of unmet medical needs for management of HIV in the region. Moreover, increase in focus & investment from leading players in the region support the growth of the HIV drugs market in the Asia-Pacific region.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/1867?utm_source=OPR

The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, stringent government regulations for the approval and commercialization of HIV drugs is expected to restrain the industry growth.

The major companies profiled in the report include

• Boehringer Ingelheim International GmbH,
• Merck & Co., Inc.,
• ViiV Healthcare,
• AbbVie,
• F. Hoffmann-La Roche Ltd.,
• Teva Pharmaceutical Industries Ltd.,
• Bristol-Myers Squibb,
• Gilead Sciences, Inc.,
• Johnson & Johnson, and
• Cipla Limited.

Table Of Content

Chapter: 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS
3.4. PRODUCT PIPELINE ANALYSIS
3.5. MARKET DYNAMICS

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/hiv-drugs-market.html?utm_source=OPR

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HIV Drug Market Growth by Top Manufacturers – Boehringer Ingelheim International GmbH, Merck & Co., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd. & Cipla Limited & Others here

News-ID: 1408906 • Views:

More Releases from Allied Market Research

Sustainable Footwear Market is Projected to Rise $13.3 billion by 2030, Growing at a CAGR of 5.7% From 2021-2030
Sustainable Footwear Market is Projected to Rise $13.3 billion by 2030, Growing …
The global sustainable footwear market was valued at $7.7 billion in 2020, and is projected to reach $13.3 billion by 2030, registering a CAGR of 5.7% from 2021 to 2030. Request The Sample PDF Of This Report: https://www.alliedmarketresearch.com/request-sample/A13792 Sustainable footwear is a type of footwear which is made by recycling waste and are manufactured by eco-friendly production process. In addition to this, surge in youth population, improved lifestyle,
Wedding Services Market to Surge USD 414.2 billion by 2030, Size, Share, Emerging Trends, Key Growth Drivers
Wedding Services Market to Surge USD 414.2 billion by 2030, Size, Share, Emergin …
The wedding services market size was valued at $160,587.40 million in 2020, and is estimated to reach $414.2 billion by 2030, growing at a CAGR of 4.8% from 2021 to 2030.Catering services segment led in terms of market share in 2020 and is expected to retain its dominance throughout the forecast period. Request The Sample PDF Of This Report @: https://www.alliedmarketresearch.com/request-sample/16233 Destination wedding is falling under wedding services market
Global Supercapacitor Market: Examining the Profitable Opportunities in the Sector
Global Supercapacitor Market: Examining the Profitable Opportunities in the Sect …
Allied Market Research recently published a report on the supercapacitor market which offers a comprehensive analysis of the industry for the 2020-2027 timeframe. As per this report, the global supercapacitor market accounted for $3.27 billion in 2019 and is set to garner $16.95 billion by 2027, thereby growing at a CAGR of 23.3% in the 2020-2027 timeframe. As part of the market analysis, the report classifies the industry into various
Balsa Core Materials Market 2024: Exploring Applications, Trends and Opportunities 2025
Balsa Core Materials Market 2024: Exploring Applications, Trends and Opportuniti …
The global balsa core materials market was valued at $199 million in 2017, and is projected to reach $291 million by 2025, growing at a CAGR of 4.8% from 2018 to 2025. The major companies profiled in this report are DIAB, Schweiter Technologies, BCOMP LTD., Carbon-Core Corp, Gurit Holding AG, Evonik Industries AG, I-Core Composites, LLC, CoreLite Inc., BONDi (Shandong) Environmental Material Company Limited, and Nord Compensati Spa. Request Sample Report

All 5 Releases


More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral